Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label intrathecal GC101 gene therapy in spinal muscular atrophy type 3
CTR20241841Phase 2Active
- Sponsor
- GeneCradle
- Start
- Aug 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of nolgileucel in Spinal muscular atrophy type 3 (SMA3), sponsored by GeneCradle. Started Aug 2024; status: active.
02
Drugs
nolgileucel
03
Conditions
Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on CTR20241841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241841.